We conducted a systematic review to compare the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus placebo in addition to insulin treatment in patients with type 1 diabetes (T1D). The gene discussed is INS; the disease is type 1 diabetes mellitus.